Novartis AG (NOVN SW / NVS), headquartered in Basel, Switzerland, is a global healthcare leader focused on innovative medicines. Following the successful spin-off of Sandoz, Novartis operates as a pure-play pharmaceuticals powerhouse centered on core therapeutic areas including cardiovascular-renal-metabolic, immunology, neuroscience, and oncology.

Novartis commands a robust pipeline and portfolio of blockbusters (such as Kesimpta, Kisqali, Pluvicto, Leqvio, and Scemblix) with multiple assets scaling past $1B–$5B in peak sales potential. Its strategic pivot toward high-margin innovative therapeutics and targeted bolt-on acquisitions (such as Avidity Biosciences and Myricx Bio) strengthens its proprietary pipeline against impending patent cliffs.

• 1H 2026 & Transitional Year Dynamics (07/22/2026): Reaffirmed guidance for a transitional 2026 characterized by a steep generic cliff in Entresto (sales down 48% cc in 1H). Management expects 2H acceleration to support low-single-digit full-year net sales growth.
• Strategic M&A Expansion: Agreed to acquire Myricx Bio for up to USD1.5B (expected close 2H 2026) to expand its oncology ADC and NMTi payload platform. This follows the massive USD12B acquisition of Avidity Biosciences in Q1 2026 adding late-stage genetic neuromuscular disease programs.
• U.S. Policy & Investment Alignment: Secured a three-year tariff exemption under a December 2025 U.S. government agreement, backed by a planned USD23B U.S. manufacturing and R&D footprint expansion over five years to ensure end-to-end domestic supply.

• Patent Cliff Exposure: Steep revenue attrition from blockbuster legacy drugs like Entresto.
• Leverage & Integration Risk: Net debt nearly doubled to USD39.4B at end-Q2 2026 following major acquisitions, placing leverage at the upper end of European pharma peers.
• Clinical & Regulatory Execution: High dependence on upcoming pivotal pipeline readouts (e.g., Pelacarsen, remibrutinib) and successful commercial scaling of new growth drivers.